Please assess the completion status of the following clinical trial:

Trial Title: Optive Brand For Day And Night Dry Eye Management

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* OSDI score of ≥ 23~* Ocular comfort at waking \<65 on 100-point scale~* Conjunctival staining Grade ≥ 2 (scale 0 to 4) in at least one eye~* Use of eyedrops for the relief of dry eye symptoms for at least one month~* Best corrected visual acuity in each eye of at least 20/25~* Have normal eyes with the exception of the need for visual correction; subjects must be willing to cease contact lens wear for the duration of the study~* Be willing and able to adhere to the instructions set in the clinical protocol and maintain the appointment schedule~Exclusion Criteria:~* Use of Benzalkonium Chloride (BAK) preserved eyedrops in the last month~* Use of Optive brand eyedrops in the last month~* Monocular participants (only one eye with functional vision).~* Contact lens wear during the study~* History of herpetic keratitis, ocular surgery or irregular cornea;~* Known pregnancy or lactation during the study period~* Participation in any clinical trial within 30 days of the enrollment visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Optive® Fusion + Optive® Gel Drop (Type: EXPERIMENTAL): Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep. The treatment regimen will be used for one month.

Based on this trial design, predict the completion outcome and termination type (if applicable).